Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01843374 · ClinicalTrials.gov registry record · Phase 2
Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma
A Phase 2 study of Unresectable Pleural or Peritoneal Malignant Mesothelioma, sponsored by MedImmune.
- Active
- Registry status
- Phase 2
- Development phase
- 571
- Enrollment target
- 20
- Study locations
NCT01843374 is a Phase 2 study of Unresectable Pleural or Peritoneal Malignant Mesothelioma that is active but no longer recruiting, run by MedImmune. The registered enrollment target is 571 participants. The trial reports 20 study locations across 14 states.
The verdict
NCT01843374, a Phase 2 study of Unresectable Pleural or Peritoneal Malignant Mesothelioma, is active but no longer recruiting, sponsored by MedImmune.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 571 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 2b, randomized, double-blind, parallel-group study. Subjects with unresectable pleural or peritoneal malignant mesothelioma will be randomized in a 2:1 ratio to receive either tremelimumab or placebo. Approximately 564 subjects will be enrolled at study centers in multiple countries. The study consists of a screening period, a treatment period, a 90-day follow-up period for safety, and a long-term survival follow-up period.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Tremelimumab
Study Locations (20)
California
- Research Site - La Jolla
- Research Site - Los Angeles
- Research Site - San Francisco
- Research Site - Santa Monica
Illinois
- Research Site - Chicago
- Research Site - Peoria
Maryland
- Research Site - Baltimore
- Research Site - Baltimore
New York
- Research Site - New York
- Research Site - Rochester
Arizona
- Research Site - Scottsdale
Connecticut
- Research Site - New Haven
Delaware
- Research Site - Newark
Florida
- Research Site - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 571 participants |
| Start Date | 2013-05-17 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01843374
The ClinicalTrials.gov registry entry for NCT01843374 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 571 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Unresectable Pleural or Peritoneal Malignant Mesothelioma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01843374 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Illinois, Maryland.
Frequently Asked Questions
What is clinical trial NCT01843374 about?
NCT01843374 is a clinical study titled "Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma". This is a Phase 2b, randomized, double-blind, parallel-group study. Subjects with unresectable pleural or peritoneal malignant mesothelioma will be randomized in a 2:1 ratio to receive either tremelimumab or placebo. Approximately 564 subjects will be enrolled at study centers in multiple countries....
What is the current status of trial NCT01843374?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 571 participants. The study started on 2013-05-17. Estimated completion is 2026-06-30.
What conditions does trial NCT01843374 study?
This clinical trial studies the following conditions: Unresectable Pleural or Peritoneal Malignant Mesothelioma.
What interventions are being tested in trial NCT01843374?
The interventions under investigation include: Placebo (DRUG), Tremelimumab (DRUG).
Who is sponsoring clinical trial NCT01843374?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01843374 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Delaware, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.